3101 Updated efficacy and safety results from a global...

European Journal of Cancer 2015 / 09 Vol. 51

3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)

Barlesi, F., Dingemans, A.M.C., Ou, I., Ahn, J.S., Petris, L.D., Kim, D.W., Yang, J.C.H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Viteri, S., Mekhail, T., Spira, A., Zeaiter, A., Bordogna,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31742-7
Date:
September, 2015
File:
PDF, 61 KB
english, 2015
Conversion to is in progress
Conversion to is failed